Our site may be slower due to heavy traffic from automated "bots" and AI crawlers. We're working to fix this.

Jennifer Clarke, MD, MPH

Photo of Jennifer Clarke, MD, MPH
Title(s)Professor, Neurology
SchoolSchool of Medicine
Address500 Parnassus Avenue, #E307
San Francisco CA 94117
ORCID ORCID Icon0000-0002-8054-7342 Additional info
vCardDownload vCard
    Other Positions
    Title(s)UCSF Weill Institute for Neurosciences


    Collapse Biography 
    Collapse education and training
    Memorial Sloan-Kettering Cancer Center, New York2008Neuro Oncology Fellowship
    University of California, San Francisco, San Francisco2006Neurology
    St. Mary's Medical Center, San Francisco, San Francisco2003Intern, Medicine
    University of California, San Francisco, San FranciscoMD2002
    University of California, Berkeley, BerkeleyMPH2001Health Policy and Management
    California Institute of Technology , PasadenaB.S.1995Chemistry
    University of California, San Francisco, CA2019Diversity, Equity, and Inclusion Champion Training

    Collapse Overview 
    Collapse overview
    Jennifer L. Clarke, MD, MPH
    Professor of Clinical Neurology and Neurological Surgery
    Division of Neuro-Oncology
    Principal Investigator, Brain Tumor Research Center

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Novel radiotherapy target definition using AI-driven predictions of glioblastoma recurrence from metabolic and diffusion MRI. NPJ Digit Med. 2025 Aug 07; 8(1):508. Tran N, Luks TL, Li Y, Jakary A, Ellison J, Liu B, Adegbite O, Nair D, Kakhandiki P, Molinaro AM, Villanueva-Meyer JE, Butowski N, Clarke JL, Chang SM, Braunstein SE, Morin O, Lin H, Lupo JM. PMID: 40775041; PMCID: PMC12331921.
      View in: PubMed   Mentions:
    2. Functional germline variants in DNA damage repair pathways are associated with altered survival in adults with glioma treated with temozolomide. Neuro Oncol. 2025 Jun 21; 27(5):1385-1398. Guerra G, Wendt G, McCoy L, Hansen HM, Kachuri L, Molinaro AM, Rice T, Guan V, Capistrano L, Hsieh A, Kalsi V, Sallee J, Taylor JW, Clarke JL, Almaraz ER, Wiencke JK, Eckel-Passow JE, Jenkins RB, Wrensch M, Francis SS. PMID: 39745907; PMCID: PMC12187373.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    3. A proof-of-concept study for patient use of open notes with large language models. JAMIA Open. 2025 Apr; 8(2):ooaf021. Salmi L, Lewis DM, Clarke JL, Dong Z, Fischmann R, McIntosh EI, Sarabu CR, DesRoches CM. PMID: 40206786; PMCID: PMC11980777.
      View in: PubMed   Mentions: 2  
    4. Longitudinal profiling of IDH-mutant astrocytomas reveals acquired RAS-MAPK pathway mutations associated with inferior survival. Neurooncol Adv. 2025 Jan-Dec; 7(1):vdaf024. Rodriguez Almaraz E, Guerra GA, Al-Adli NN, Young JS, Dada A, Quintana D, Taylor JW, Oberheim Bush NA, Clarke JL, Butowski NA, de Groot J, Pekmezci M, Perry A, Bollen AW, Scheffler AW, Glidden DV, Phillips JJ, Costello JF, Chang EF, Hervey-Jumper S, Berger MS, Francis SS, Chang SM, Solomon DA. PMID: 40051658; PMCID: PMC11883348.
      View in: PubMed   Mentions:
    5. Longitudinal multimodal profiling of IDH-wildtype glioblastoma reveals the molecular evolution and cellular phenotypes underlying prognostically different treatment responses. Neuro Oncol. 2025 Jan 12; 27(1):89-105. Lucas CG, Al-Adli NN, Young JS, Gupta R, Morshed RA, Wu J, Ravindranathan A, Shai A, Oberheim Bush NA, Taylor JW, de Groot J, Villanueva-Meyer JE, Pekmezci M, Perry A, Bollen AW, Theodosopoulos PV, Aghi MK, Chang EF, Hervey-Jumper SL, Raleigh DR, Molinaro AM, Costello JF, Diaz AA, Clarke JL, Butowski NA, Phillips JJ, Chang SM, Berger MS, Solomon DA. PMID: 39560080; PMCID: PMC11726253.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    6. Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort. Nat Commun. 2024 12 30; 15(1):10757. McFaline-Figueroa JR, Sun L, Youssef GC, Huang R, Li G, Kim J, Lee EQ, Nayak L, Chukwueke U, Beroukhim R, Batchelor TT, Chiocca EA, Everson RG, Doherty L, Stefanik J, Partridge K, Spearman A, Myers A, Westergaard C, Russ A, Lavallee M, Smokovich A, LaForest-Roys C, Garcia Fox R, McCluskey C, Bi WL, Arnaout O, Peruzzi P, Cosgrove GR, Ligon KL, Arrillaga-Romany I, Clarke JL, Reardon DA, Cloughesy TF, Prins RM, Wen PY. PMID: 39737895; PMCID: PMC11685579.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    7. Functional germline variants in DNA damage repair pathways are associated with altered survival in adults with glioma treated with temozolomide. medRxiv. 2024 Oct 10. Guerra G, Wendt G, McCoy L, Hansen HM, Kachuri L, Molinaro AM, Rice T, Guan V, Capistrano L, Hsieh A, Kalsi V, Sallee J, Taylor JW, Clarke JL, Rodriguez Almaraz E, Wiencke JK, Eckel-Passow JE, Jenkins RB, Wrensch M, Francis SS. PMID: 39417102; PMCID: PMC11482862.
      View in: PubMed   Mentions:
    8. Oligodendroglioma patient survival is associated with circulating B-cells and age. Neurooncol Adv. 2024 Jan-Dec; 6(1):vdae143. Taylor JW, Warrier G, Hansen HM, McCoy L, Rice T, Guerra G, Francis SS, Clarke JL, Bracci PM, Hadad S, Kelsey KT, Wrensch M, Molinaro AM, Wiencke JK. PMID: 39247497; PMCID: PMC11379917.
      View in: PubMed   Mentions: 1  
    9. No drug holidays in BRAFV600E glioma patients: An argument for dose reduction of targeted therapies. Neurooncol Pract. 2024 Oct; 11(5):660-664. Bazer DA, Kolchinski A, Bush NAO, Clarke JL, Bagley SJ, Schreck KC. PMID: 39279775; PMCID: PMC11398919.
      View in: PubMed   Mentions: 1  
    10. Automatic Brain Tissue and Lesion Segmentation and Multi-Parametric Mapping of Contrast-Enhancing Gliomas without the Injection of Contrast Agents: A Preliminary Study. Cancers (Basel). 2024 Apr 17; 16(8). Liu J, Jakary A, Villanueva-Meyer JE, Butowski NA, Saloner D, Clarke JL, Taylor JW, Oberheim Bush NA, Chang SM, Xu D, Lupo JM. PMID: 38672606; PMCID: PMC11049314.
      View in: PubMed   Mentions: 2  
    11. Prebiotic proanthocyanidins inhibit bile reflux-induced esophageal adenocarcinoma through reshaping the gut microbiome and esophageal metabolome. JCI Insight. 2024 02 08; 9(6). Weh KM, Howard CL, Zhang Y, Tripp BA, Clarke JL, Howell AB, Rubenstein JH, Abrams JA, Westerhoff M, Kresty LA. PMID: 38329812; PMCID: PMC11063939.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimals
    12. A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas. Neuro Oncol. 2024 02 02; 26(2):335-347. Saijo A, Ogino H, Butowski NA, Tedesco MR, Gibson D, Watchmaker PB, Okada K, Wang AS, Shai A, Salazar AM, Molinaro AM, Rabbitt JE, Shahin M, Perry A, Clarke JL, Taylor JW, Daras M, Oberheim Bush NA, Hervey-Jumper SL, Phillips JJ, Chang SM, Hilf N, Mayer-Mokler A, Keler T, Berger MS, Okada H. PMID: 37758193; PMCID: PMC10836773.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    13. Advanced Hyperpolarized 13C Metabolic Imaging Protocol for Patients with Gliomas: A Comprehensive Multimodal MRI Approach. Cancers (Basel). 2024 Jan 13; 16(2). Autry AW, Vaziri S, Gordon JW, Chen HY, Kim Y, Dang D, LaFontaine M, Noeske R, Bok R, Villanueva-Meyer JE, Clarke JL, Oberheim Bush NA, Chang SM, Xu D, Lupo JM, Larson PEZ, Vigneron DB, Li Y. PMID: 38254844; PMCID: PMC10814348.
      View in: PubMed   Mentions: 3  
    14. Current challenges and future of agricultural genomes to phenomes in the USA. Genome Biol. 2024 01 03; 25(1):8. Tuggle CK, Clarke JL, Murdoch BM, Lyons E, Scott NM, Beneš B, Campbell JD, Chung H, Daigle CL, Das Choudhury S, Dekkers JCM, Dórea JRR, Ertl DS, Feldman M, Fragomeni BO, Fulton JE, Guadagno CR, Hagen DE, Hess AS, Kramer LM, Lawrence-Dill CJ, Lipka AE, Lübberstedt T, McCarthy FM, McKay SD, Murray SC, Riggs PK, Rowan TN, Sheehan MJ, Steibel JP, Thompson AM, Thornton KJ, Van Tassell CP, Schnable PS. PMID: 38172911; PMCID: PMC10763150.
      View in: PubMed   Mentions: 6     Fields:    
    15. Author Correction: Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial. Nat Med. 2024 Jan; 30(1):302. Mellinghoff IK, Lu M, Wen PY, Taylor JW, Maher EA, Arrillaga-Romany I, Peters KB, Ellingson BM, Rosenblum MK, Chun S, Le K, Tassinari A, Choe S, Toubouti Y, Schoenfeld S, Pandya SS, Hassan I, Steelman L, Clarke JL, Cloughesy TF. PMID: 37400643; PMCID: PMC10803248.
      View in: PubMed   Mentions: 1     Fields:    
    16. "De novo replication repair deficient glioblastoma, IDH-wildtype" is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockade. Acta Neuropathol. 2023 12 11; 147(1):3. Hadad S, Gupta R, Oberheim Bush NA, Taylor JW, Villanueva-Meyer JE, Young JS, Wu J, Ravindranathan A, Zhang Y, Warrier G, McCoy L, Shai A, Pekmezci M, Perry A, Bollen AW, Phillips JJ, Braunstein SE, Raleigh DR, Theodosopoulos P, Aghi MK, Chang EF, Hervey-Jumper SL, Costello JF, de Groot J, Butowski NA, Clarke JL, Chang SM, Berger MS, Molinaro AM, Solomon DA. PMID: 38079020; PMCID: PMC10713691.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    17. Cranberry Proanthocyanidins Mitigate Reflux-Induced Transporter Dysregulation in an Esophageal Adenocarcinoma Model. Pharmaceuticals (Basel). 2023 Dec 07; 16(12). Zhang Y, Weh KM, Tripp BA, Clarke JL, Howard CL, Sunilkumar S, Howell AB, Kresty LA. PMID: 38139823; PMCID: PMC10747310.
      View in: PubMed   Mentions: 2  
    18. Data sharing and ontology use among agricultural genetics, genomics, and breeding databases and resources of the Agbiodata Consortium. Database (Oxford). 2023 11 15; 2023. Clarke JL, Cooper LD, Poelchau MF, Berardini TZ, Elser J, Farmer AD, Ficklin S, Kumari S, Laporte MA, Nelson RT, Sadohara R, Selby P, Thessen AE, Whitehead B, Sen TZ. PMID: 37971715; PMCID: PMC10653126.
      View in: PubMed   Mentions: 2     Fields:    Translation:Animals
    19. Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma. J Neurooncol. 2023 Oct; 165(1):101-112. Strowd R, Ellingson B, Raymond C, Yao J, Wen PY, Ahluwalia M, Piotrowski A, Desai A, Clarke JL, Lieberman FS, Desideri S, Nabors LB, Ye X, Grossman S. PMID: 37864646; PMCID: PMC10863646.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    20. Multi-parametric hyperpolarized 13C/1H imaging reveals Warburg-related metabolic dysfunction and associated regional heterogeneity in high-grade human gliomas. Neuroimage Clin. 2023; 39:103501. Autry AW, Vaziri S, LaFontaine M, Gordon JW, Chen HY, Kim Y, Villanueva-Meyer JE, Molinaro A, Clarke JL, Oberheim Bush NA, Xu D, Lupo JM, Larson PEZ, Vigneron DB, Chang SM, Li Y. PMID: 37611371; PMCID: PMC10470324.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    21. Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial. Nat Med. 2023 03; 29(3):615-622. Mellinghoff IK, Lu M, Wen PY, Taylor JW, Maher EA, Arrillaga-Romany I, Peters KB, Ellingson BM, Rosenblum MK, Chun S, Le K, Tassinari A, Choe S, Toubouti Y, Schoenfeld S, Pandya SS, Hassan I, Steelman L, Clarke JL, Cloughesy TF. PMID: 36823302; PMCID: PMC10313524.
      View in: PubMed   Mentions: 85     Fields:    Translation:HumansCTClinical Trials
    22. Evaluation of cross-platform compatibility of a DNA methylation-based glucocorticoid response biomarker. Clin Epigenetics. 2022 10 28; 14(1):136. Tang E, Wiencke JK, Warrier G, Hansen H, McCoy L, Rice T, Bracci PM, Wrensch M, Taylor JW, Clarke JL, Koestler DC, Salas LA, Christensen BC, Kelsey KT, Molinaro AM. PMID: 36307860; PMCID: PMC9617416.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    23. Prospective genomically guided identification of "early/evolving" and "undersampled" IDH-wildtype glioblastoma leads to improved clinical outcomes. Neuro Oncol. 2022 10 03; 24(10):1749-1762. Zhang Y, Lucas CG, Young JS, Morshed RA, McCoy L, Oberheim Bush NA, Taylor JW, Daras M, Butowski NA, Villanueva-Meyer JE, Cha S, Wrensch M, Wiencke JK, Lee JC, Pekmezci M, Phillips JJ, Perry A, Bollen AW, Aghi MK, Theodosopoulos P, Chang EF, Hervey-Jumper SL, Berger MS, Clarke JL, Chang SM, Molinaro AM, Solomon DA. PMID: 35395677; PMCID: PMC9527525.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    24. Assessment of higher-order singular value decomposition denoising methods on dynamic hyperpolarized [1-13C]pyruvate MRI data from patients with glioma. Neuroimage Clin. 2022; 36:103155. Vaziri S, Autry AW, Lafontaine M, Kim Y, Gordon JW, Chen HY, Hu JY, Lupo JM, Chang SM, Clarke JL, Villanueva-Meyer JE, Bush NAO, Xu D, Larson PEZ, Vigneron DB, Li Y. PMID: 36007439; PMCID: PMC9421383.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    25. Characterizing isoform switching events in esophageal adenocarcinoma. Mol Ther Nucleic Acids. 2022 Sep 13; 29:749-768. Zhang Y, Weh KM, Howard CL, Riethoven JJ, Clarke JL, Lagisetty KH, Lin J, Reddy RM, Chang AC, Beer DG, Kresty LA. PMID: 36090744; PMCID: PMC9437810.
      View in: PubMed   Mentions: 11  
    26. Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. Acta Neuropathol. 2022 10; 144(4):747-765. Lucas CG, Sloan EA, Gupta R, Wu J, Pratt D, Vasudevan HN, Ravindranathan A, Barreto J, Williams EA, Shai A, Whipple NS, Bruggers CS, Maher O, Nabors B, Rodriguez M, Samuel D, Brown M, Carmichael J, Lu R, Mirchia K, Sullivan DV, Pekmezci M, Tihan T, Bollen AW, Perry A, Banerjee A, Mueller S, Gupta N, Hervey-Jumper SL, Oberheim Bush NA, Daras M, Taylor JW, Butowski NA, de Groot J, Clarke JL, Raleigh DR, Costello JF, Phillips JJ, Reddy AT, Chang SM, Berger MS, Solomon DA. PMID: 35945463; PMCID: PMC9468105.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    27. Pre-surgery immune profiles of adult glioma patients. J Neurooncol. 2022 Aug; 159(1):103-115. Bracci PM, Rice T, Hansen HM, Francis SS, Lee S, McCoy LS, Shrestha PP, Warrier G, Clarke JL, Molinaro AM, Taylor JW, Wiencke JK, Wrensch MR. PMID: 35716311; PMCID: PMC9325836.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    28. Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma. Clin Cancer Res. 2022 06 13; 28(12):2567-2578. Nayak L, Standifer N, Dietrich J, Clarke JL, Dunn GP, Lim M, Cloughesy T, Gan HK, Flagg E, George E, Gaffey S, Hayden J, Holcroft C, Wen PY, Macri M, Park AJ, Ricciardi T, Ryan A, Schwarzenberger P, Venhaus R, Reyes ML, Durham NM, Creasy T, Huang RY, Kaley T, Reardon DA. PMID: 35395080; PMCID: PMC9940445.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    29. Combining radiomics and deep convolutional neural network features from preoperative MRI for predicting clinically relevant genetic biomarkers in glioblastoma. Neurooncol Adv. 2022 Jan-Dec; 4(1):vdac060. Calabrese E, Rudie JD, Rauschecker AM, Villanueva-Meyer JE, Clarke JL, Solomon DA, Cha S. PMID: 35611269; PMCID: PMC9122791.
      View in: PubMed   Mentions: 34  
    30. Ten simple rules to ruin a collaborative environment. PLoS Comput Biol. 2022 04; 18(4):e1009957. Lawrence-Dill CJ, Allscheid RL, Boaitey A, Bauman T, Buckler ES, Clarke JL, Cullis C, Dekkers J, Dorius CJ, Dorius SF, Ertl D, Homann M, Hu G, Losch M, Lyons E, Murdoch B, Navabi ZK, Punnuri S, Rafiq F, Reecy JM, Schnable PS, Scott NM, Sheehan M, Sirault X, Staton M, Tuggle CK, Van Eenennaam A, Voas R. PMID: 35421080; PMCID: PMC9009642.
      View in: PubMed   Mentions: 1     Fields:    
    31. Interactions of Age and Blood Immune Factors and Noninvasive Prediction of Glioma Survival. J Natl Cancer Inst. 2022 03 08; 114(3):446-457. Molinaro AM, Wiencke JK, Warrier G, Koestler DC, Chunduru P, Lee JY, Hansen HM, Lee S, Anguiano J, Rice T, Bracci PM, McCoy L, Salas LA, Christensen BC, Wrensch M, Kelsey KT, Taylor JW, Clarke JL. PMID: 34597382; PMCID: PMC8902347.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    32. Cranberry Polyphenols in Esophageal Cancer Inhibition: New Insights. Nutrients. 2022 Feb 24; 14(5). Weh KM, Zhang Y, Howard CL, Howell AB, Clarke JL, Kresty LA. PMID: 35267943; PMCID: PMC8912450.
      View in: PubMed   Mentions: 8     Fields:    Translation:Animals
    33. Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas. J Clin Invest. 2022 02 01; 132(3). Ogino H, Taylor JW, Nejo T, Gibson D, Watchmaker PB, Okada K, Saijo A, Tedesco MR, Shai A, Wong CM, Rabbitt JE, Olin MR, Moertel CL, Nishioka Y, Salazar AM, Molinaro AM, Phillips JJ, Butowski NA, Clarke JL, Oberheim Bush NA, Hervey-Jumper SL, Theodosopoulos P, Chang SM, Berger MS, Okada H. PMID: 34882581; PMCID: PMC8803342.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCellsPHPublic Health
    34. The application of the skin virome for human identification. Forensic Sci Int Genet. 2022 03; 57:102662. Graham EH, Clarke JL, Fernando SC, Herr JR, Adamowicz MS. PMID: 35066408.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    35. EWSR1-BEND2 fusion defines an epigenetically distinct subtype of astroblastoma. Acta Neuropathol. 2022 01; 143(1):109-113. Lucas CG, Gupta R, Wu J, Shah K, Ravindranathan A, Barreto J, Gener M, Ginn KF, Prall OWJ, Xu H, Kee D, Ko HS, Yaqoob N, Zia N, Florez A, Cha S, Perry A, Clarke JL, Chang SM, Berger MS, Solomon DA. PMID: 34825267; PMCID: PMC8732961.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    36. Proanthocyanidins mitigate bile acid-induced changes in GSTT2 levels in a panel of racially diverse patient-derived primary esophageal cell cultures. Mol Carcinog. 2022 03; 61(3):281-287. Weh KM, Turgeon DK, Rubenstein JH, Clarke JL, Howell AB, Chang AC, Kresty LA. PMID: 34758158; PMCID: PMC8837669.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    37. Diffuse hemispheric glioma, H3 G34-mutant: Genomic landscape of a new tumor entity and prospects for targeted therapy. Neuro Oncol. 2021 11 02; 23(11):1974-1976. Lucas CG, Mueller S, Reddy A, Taylor JW, Oberheim Bush NA, Clarke JL, Chang SM, Gupta N, Berger MS, Perry A, Phillips JJ, Solomon DA. PMID: 34519829; PMCID: PMC8628364.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    38. Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas. Neuro Oncol. 2021 11 02; 23(11):1872-1884. Yu Y, Villanueva-Meyer J, Grimmer MR, Hilz S, Solomon DA, Choi S, Wahl M, Mazor T, Hong C, Shai A, Phillips JJ, Wainer BH, McDermott M, Haas-Kogan D, Taylor JW, Butowski N, Clarke JL, Berger MS, Molinaro AM, Chang SM, Costello JF, Oberheim Bush NA. PMID: 33823014; PMCID: PMC8563321.
      View in: PubMed   Mentions: 60     Fields:    Translation:Humans
    39. A multicenter analysis of the prognostic value of histone H3 K27M mutation in adult high-grade spinal glioma. J Neurosurg Spine. 2021 12 01; 35(6):834-843. Akinduro OO, Garcia DP, Higgins DMO, Vivas-Buitrago T, Jentoft M, Solomon DA, Daniels DJ, Pennington Z, Sherman WJ, Delgardo M, Bydon M, Kalani MA, Zanazzi G, Tsankova N, Bendok BR, McCormick PC, Sciubba DM, Lo SL, Clarke JL, Abode-Iyamah K, Quiñones-Hinojosa A. PMID: 34416733.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    40. Low-grade glioneuronal tumors with FGFR2 fusion resolve into a single epigenetic group corresponding to 'Polymorphous low-grade neuroepithelial tumor of the young'. Acta Neuropathol. 2021 09; 142(3):595-599. Gupta R, Lucas CG, Wu J, Barreto J, Shah K, Simon IB, Casavilca-Zambrano S, Brathwaite C, Zhou H, Caccamo D, Gilani A, Kleinschmidt-DeMasters BK, Lee JC, Perry A, Clarke JL, Chang SM, Berger MS, Solomon DA. PMID: 34322742; PMCID: PMC8357689.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    41. Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial. Clin Cancer Res. 2021 08 15; 27(16):4491-4499. Mellinghoff IK, Penas-Prado M, Peters KB, Burris HA, Maher EA, Janku F, Cote GM, de la Fuente MI, Clarke JL, Ellingson BM, Chun S, Young RJ, Liu H, Choe S, Lu M, Le K, Hassan I, Steelman L, Pandya SS, Cloughesy TF, Wen PY. PMID: 34078652; PMCID: PMC8364866.
      View in: PubMed   Mentions: 116     Fields:    Translation:HumansCTClinical Trials
    42. Proof-of-concept single-arm trial of bevacizumab therapy for brain arteriovenous malformation. BMJ Neurol Open. 2021; 3(1):e000114. Muster R, Ko N, Smith W, Su H, Dickey MA, Nelson J, McCulloch CE, Sneed PK, Clarke JL, Saloner DA, Eisenmenger L, Kim H, Cooke DL. PMID: 34189463; PMCID: PMC8204171.
      View in: PubMed   Mentions: 9  
    43. Current Advances in Immunotherapy for Glioblastoma. Curr Oncol Rep. 2021 01 26; 23(2):21. Mende AL, Schulte JD, Okada H, Clarke JL. PMID: 33496872; PMCID: PMC7838142.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    44. Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. Clin Cancer Res. 2021 02 15; 27(4):1048-1057. Nayak L, Molinaro AM, Peters K, Clarke JL, Jordan JT, de Groot J, Nghiemphu L, Kaley T, Colman H, McCluskey C, Gaffey S, Smith TR, Cote DJ, Severgnini M, Yearley JH, Zhao Q, Blumenschein WM, Duda DG, Muzikansky A, Jain RK, Wen PY, Reardon DA. PMID: 33199490; PMCID: PMC8284901.
      View in: PubMed   Mentions: 160     Fields:    Translation:HumansCTClinical Trials
    45. Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adults. Neurooncol Adv. 2020 Jan-Dec; 2(1):vdaa142. Schulte JD, Buerki RA, Lapointe S, Molinaro AM, Zhang Y, Villanueva-Meyer JE, Perry A, Phillips JJ, Tihan T, Bollen AW, Pekmezci M, Butowski N, Oberheim Bush NA, Taylor JW, Chang SM, Theodosopoulos P, Aghi MK, Hervey-Jumper SL, Berger MS, Solomon DA, Clarke JL. PMID: 33354667; PMCID: PMC7739048.
      View in: PubMed   Mentions: 53  
    46. Comprehensive analysis of diverse low-grade neuroepithelial tumors with FGFR1 alterations reveals a distinct molecular signature of rosette-forming glioneuronal tumor. Acta Neuropathol Commun. 2020 08 28; 8(1):151. Lucas CG, Gupta R, Doo P, Lee JC, Cadwell CR, Ramani B, Hofmann JW, Sloan EA, Kleinschmidt-DeMasters BK, Lee HS, Wood MD, Grafe M, Born D, Vogel H, Salamat S, Puccetti D, Scharnhorst D, Samuel D, Cooney T, Cham E, Jin LW, Khatib Z, Maher O, Chamyan G, Brathwaite C, Bannykh S, Mueller S, Kline CN, Banerjee A, Reddy A, Taylor JW, Clarke JL, Oberheim Bush NA, Butowski N, Gupta N, Auguste KI, Sun PP, Roland JL, Raffel C, Aghi MK, Theodosopoulos P, Chang E, Hervey-Jumper S, Phillips JJ, Pekmezci M, Bollen AW, Tihan T, Chang S, Berger MS, Perry A, Solomon DA. PMID: 32859279; PMCID: PMC7456392.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    47. Characterization of serial hyperpolarized 13C metabolic imaging in patients with glioma. Neuroimage Clin. 2020; 27:102323. Autry AW, Gordon JW, Chen HY, LaFontaine M, Bok R, Van Criekinge M, Slater JB, Carvajal L, Villanueva-Meyer JE, Chang SM, Clarke JL, Lupo JM, Xu D, Larson PEZ, Vigneron DB, Li Y. PMID: 32623139; PMCID: PMC7334458.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    48. Post-ER Stress Biogenesis of Golgi Is Governed by Giantin. Cells. 2019 12 13; 8(12). Frisbie CP, Lushnikov AY, Krasnoslobodtsev AV, Riethoven JM, Clarke JL, Stepchenkova EI, Petrosyan A. PMID: 31847122; PMCID: PMC6953117.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    49. Treatment-induced lesions in newly diagnosed glioblastoma patients undergoing chemoradiotherapy and heat-shock protein vaccine therapy. J Neurooncol. 2020 Jan; 146(1):71-78. Alcaide-Leon P, Luks TL, Lafontaine M, Lupo JM, Okada H, Clarke JL, Villanueva-Meyer JE. PMID: 31728884; PMCID: PMC6939141.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    50. Recurrent non-canonical histone H3 mutations in spinal cord diffuse gliomas. Acta Neuropathol. 2019 11; 138(5):877-881. Sloan EA, Cooney T, Oberheim Bush NA, Buerki R, Taylor J, Clarke JL, Torkildson J, Kline C, Reddy A, Mueller S, Banerjee A, Butowski N, Chang S, Mummaneni PV, Chou D, Tan L, Theodosopoulos P, McDermott M, Berger M, Raffel C, Gupta N, Sun PP, Li Y, Shah V, Cha S, Braunstein S, Raleigh DR, Samuel D, Scharnhorst D, Fata C, Guo H, Moes G, Kim JYH, Koschmann C, Van Ziffle J, Onodera C, Devine P, Grenert JP, Lee JC, Pekmezci M, Phillips JJ, Tihan T, Bollen AW, Perry A, Solomon DA. PMID: 31515627; PMCID: PMC6818961.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    51. Reirradiation of recurrent high-grade glioma and development of prognostic scores for progression and survival. Neurooncol Pract. 2019 Sep; 6(5):364-374. Chapman CH, Hara JH, Molinaro AM, Clarke JL, Oberheim Bush NA, Taylor JW, Butowski NA, Chang SM, Fogh SE, Sneed PK, Nakamura JL, Raleigh DR, Braunstein SE. PMID: 31555451; PMCID: PMC6753361.
      View in: PubMed   Mentions: 22  
    52. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019 03; 25(3):477-486. Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM, Kawaguchi ES, Du L, Li G, Yong WH, Gaffey SC, Cohen AL, Mellinghoff IK, Lee EQ, Reardon DA, O'Brien BJ, Butowski NA, Nghiemphu PL, Clarke JL, Arrillaga-Romany IC, Colman H, Kaley TJ, de Groot JF, Liau LM, Wen PY, Prins RM. PMID: 30742122; PMCID: PMC6408961.
      View in: PubMed   Mentions: 793     Fields:    Translation:HumansCells
    53. Risk factors of radiotherapy-induced cerebral microbleeds and serial analysis of their size compared with white matter changes: A 7T MRI study in 113 adult patients with brain tumors. J Magn Reson Imaging. 2019 09; 50(3):868-877. Morrison MA, Hess CP, Clarke JL, Butowski N, Chang SM, Molinaro AM, Lupo JM. PMID: 30663150; PMCID: PMC6642688.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansPHPublic Health
    54. Attitudes toward fertility and fertility preservation in women with glioma. Neurooncol Pract. 2019 May; 6(3):218-225. Stiner RK, Clarke JL, Sinha N, Chan J, Letourneau JM, Niemasik EE, Rabbitt JE, Chang SM, Butowski NA, Prados MD, Rosen MP. PMID: 31386027; PMCID: PMC6656302.
      View in: PubMed   Mentions: 6  
    55. Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma. J Neurooncol. 2018 Nov; 140(2):477-483. Taylor JW, Parikh M, Phillips JJ, James CD, Molinaro AM, Butowski NA, Clarke JL, Oberheim-Bush NA, Chang SM, Berger MS, Prados M. PMID: 30151703; PMCID: PMC6239922.
      View in: PubMed   Mentions: 71     Fields:    Translation:HumansCTClinical Trials
    56. The genetic landscape of ganglioglioma. Acta Neuropathol Commun. 2018 06 07; 6(1):47. Pekmezci M, Villanueva-Meyer JE, Goode B, Van Ziffle J, Onodera C, Grenert JP, Bastian BC, Chamyan G, Maher OM, Khatib Z, Kleinschmidt-DeMasters BK, Samuel D, Mueller S, Banerjee A, Clarke JL, Cooney T, Torkildson J, Gupta N, Theodosopoulos P, Chang EF, Berger M, Bollen AW, Perry A, Tihan T, Solomon DA. PMID: 29880043; PMCID: PMC5992851.
      View in: PubMed   Mentions: 89     Fields:    Translation:HumansCells
    57. Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas. Neuro Oncol. 2018 04 09; 20(5):632-641. Hayes J, Yu Y, Jalbert LE, Mazor T, Jones LE, Wood MD, Walsh KM, Bengtsson H, Hong C, Oberndorfer S, Roetzer T, Smirnov IV, Clarke JL, Aghi MK, Chang SM, Nelson SJ, Woehrer A, Phillips JJ, Solomon DA, Costello JF. PMID: 29077933; PMCID: PMC5892142.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    58. Short term dynamics of the sputum microbiome among COPD patients. PLoS One. 2018; 13(3):e0191499. Sinha R, Weissenburger-Moser LA, Clarke JL, Smith LM, Heires AJ, Romberger DJ, LeVan TD. PMID: 29518088; PMCID: PMC5843169.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansPHPublic Health
    59. Survivorship care planning in neuro-oncology. Neurooncol Pract. 2018 Mar; 5(1):3-9. Leeper HE, Acquaye AA, Bell S, Clarke JL, Forst D, Laack NN, Link MJ, Taylor JW, Armstrong TS. PMID: 31386011; PMCID: PMC6655526.
      View in: PubMed   Mentions: 9  
    60. Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma. Clin Cancer Res. 2018 01 15; 24(2):295-305. Byron SA, Tran NL, Halperin RF, Phillips JJ, Kuhn JG, de Groot JF, Colman H, Ligon KL, Wen PY, Cloughesy TF, Mellinghoff IK, Butowski NA, Taylor JW, Clarke JL, Chang SM, Berger MS, Molinaro AM, Maggiora GM, Peng S, Nasser S, Liang WS, Trent JM, Berens ME, Carpten JD, Craig DW, Prados MD. PMID: 29074604; PMCID: PMC7516926.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    61. Probing the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low-grade gliomas. Cancer. 2017 Dec 01; 123(23):4631-4639. Wahl M, Chang SM, Phillips JJ, Molinaro AM, Costello JF, Mazor T, Alexandrescu S, Lupo JM, Nelson SJ, Berger M, Prados M, Taylor JW, Butowski N, Clarke JL, Haas-Kogan D. PMID: 28759109; PMCID: PMC5693663.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    62. A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma. Cancer Chemother Pharmacol. 2017 03; 79(3):603-610. Clarke JL, Molinaro AM, Cabrera JR, DeSilva AA, Rabbitt JE, Prey J, Drummond DC, Kim J, Noble C, Fitzgerald JB, Chang SM, Butowski NA, Taylor JW, Park JW, Prados MD. PMID: 28233053.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    63. Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide. Neuro Oncol. 2017 02 01; 19(2):242-251. Wahl M, Phillips JJ, Molinaro AM, Lin Y, Perry A, Haas-Kogan DA, Costello JF, Dayal M, Butowski N, Clarke JL, Prados M, Nelson S, Berger MS, Chang SM. PMID: 27571885; PMCID: PMC5464133.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansCTClinical Trials
    64. Glioma FMISO PET/MR Imaging Concurrent with Antiangiogenic Therapy: Molecular Imaging as a Clinical Tool in the Burgeoning Era of Personalized Medicine. Biomedicines. 2016 Oct 31; 4(4). Barajas RF, Krohn KA, Link JM, Hawkins RA, Clarke JL, Pampaloni MH, Cha S. PMID: 28536391; PMCID: PMC5344267.
      View in: PubMed   Mentions: 6  
    65. Histopathologic review of pineal parenchymal tumors identifies novel morphologic subtypes and prognostic factors for outcome. Neuro Oncol. 2017 01; 19(1):78-88. Raleigh DR, Solomon DA, Lloyd SA, Lazar A, Garcia MA, Sneed PK, Clarke JL, McDermott MW, Berger MS, Tihan T, Haas-Kogan DA. PMID: 27282397; PMCID: PMC5193017.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    66. Case-Based Review: meningioma. Neurooncol Pract. 2016 Jun; 3(2):120-134. Fogh SE, Johnson DR, Barker FG, Brastianos PK, Clarke JL, Kaufmann TJ, Oberndorfer S, Preusser M, Raghunathan A, Santagata S, Theodosopoulos PV. PMID: 31386096; PMCID: PMC6668267.
      View in: PubMed   Mentions: 5  
    67. Clinical outcome and prognostic factors for central neurocytoma: twenty year institutional experience. J Neurooncol. 2016 Jan; 126(1):193-200. Imber BS, Braunstein SE, Wu FY, Nabavizadeh N, Boehling N, Weinberg VK, Tihan T, Barnes M, Mueller S, Butowski NA, Clarke JL, Chang SM, McDermott MM, Prados MD, Berger MS, Haas-Kogan DA. PMID: 26493740; PMCID: PMC4826306.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    68. The Effect of Timing of Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma. Neurosurgery. 2015 Aug; 77(2):248-53; discussion 253. Han SJ, Rutledge WC, Molinaro AM, Chang SM, Clarke JL, Prados MD, Taylor JW, Berger MS, Butowski NA. PMID: 25856113; PMCID: PMC4506198.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    69. Impact of Timing of Concurrent Chemoradiation for Newly Diagnosed Glioblastoma: A Critical Review of Current Evidence. Neurosurgery. 2015 Aug; 62 Suppl 1:160-5. Han SJ, Englot DJ, Birk H, Molinaro AM, Chang SM, Clarke JL, Prados MD, Taylor JW, Berger MS, Butowski NA. PMID: 26181937; PMCID: PMC5260825.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    70. Case-Based Review: newly diagnosed glioblastoma. Neurooncol Pract. 2015 Sep; 2(3):106-121. Johnson DR, Fogh SE, Giannini C, Kaufmann TJ, Raghunathan A, Theodosopoulos PV, Clarke JL. PMID: 31386093; PMCID: PMC6668273.
      View in: PubMed   Mentions: 10  
    71. Assessing Biological Response to Bevacizumab Using 18F-Fluoromisonidazole PET/MR Imaging in a Patient with Recurrent Anaplastic Astrocytoma. Case Rep Radiol. 2015; 2015:731361. Barajas RF, Pampaloni MH, Clarke JL, Seo Y, Savic D, Hawkins RA, Behr SC, Chang SM, Berger M, Dillon WP, Cha S. PMID: 25793136; PMCID: PMC4352456.
      View in: PubMed   Mentions: 11  
    72. Standardization and quality assurance of radiation therapy volumes for adults with high-grade gliomas. Semin Radiat Oncol. 2014 Oct; 24(4):259-64. Fogh S, Wahl M, Anwar M, Haas-Kogan D, Clarke JL, Sneed PK. PMID: 25219810.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    73. Bevacizumab and other targeted agents in the upfront treatment of glioblastoma. Semin Radiat Oncol. 2014 Oct; 24(4):273-8. Clarke JL. PMID: 25219812.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    74. Familial gliomas: cases in two pairs of brothers. J Neurooncol. 2015 Jan; 121(1):135-40. Osorio JA, Hervey-Jumper SL, Walsh KM, Clarke JL, Butowski NA, Prados MD, Berger MS. PMID: 25208478.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    75. Process evaluation design in a cluster randomised controlled childhood obesity prevention trial: the WAVES study. Int J Behav Nutr Phys Act. 2014 Sep 10; 11:112. Griffin TL, Pallan MJ, Clarke JL, Lancashire ER, Lyon A, Parry JM, Adab P, WAVES study trial investigators. PMID: 25212062; PMCID: PMC4172839.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    76. A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma. Neuro Oncol. 2014 Jul; 16(7):984-90. Clarke JL, Molinaro AM, Phillips JJ, Butowski NA, Chang SM, Perry A, Costello JF, DeSilva AA, Rabbitt JE, Prados MD. PMID: 24637230; PMCID: PMC4057142.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCTClinical Trials
    77. Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma. Neuro Oncol. 2014 Sep; 16(9):1255-62. Han SJ, Rolston JD, Molinaro AM, Clarke JL, Prados MD, Chang SM, Berger MS, DeSilva A, Butowski NA. PMID: 24670608; PMCID: PMC4136897.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCellsCTClinical Trials
    78. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro Oncol. 2014 Jan; 16(2):274-9. Bloch O, Crane CA, Fuks Y, Kaur R, Aghi MK, Berger MS, Butowski NA, Chang SM, Clarke JL, McDermott MW, Prados MD, Sloan AE, Bruce JN, Parsa AT. PMID: 24335700; PMCID: PMC3895386.
      View in: PubMed   Mentions: 145     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    79. Relationship of glioblastoma multiforme to the subventricular zone is associated with survival. Neuro Oncol. 2013 Jan; 15(1):91-6. Jafri NF, Clarke JL, Weinberg V, Barani IJ, Cha S. PMID: 23095230; PMCID: PMC3534420.
      View in: PubMed   Mentions: 119     Fields:    Translation:HumansCells
    80. Neoplastic myelopathy. Semin Neurol. 2012 Apr; 32(2):137-45. Nagpal S, Clarke JL. PMID: 22961188.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    81. Leptomeningeal metastasis from systemic cancer. Continuum (Minneap Minn). 2012 Apr; 18(2):328-42. Clarke JL. PMID: 22810130.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    82. Neurosurgical management and prognosis of patients with glioblastoma that progresses during bevacizumab treatment. Neurosurgery. 2012 Feb; 70(2):361-70. Clark AJ, Lamborn KR, Butowski NA, Chang SM, Prados MD, Clarke JL, McDermott MW, Parsa AT, Berger MS, Aghi MK. PMID: 21841523.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    83. Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol. 2012 Feb; 7(2):382-5. Morris PG, Reiner AS, Szenberg OR, Clarke JL, Panageas KS, Perez HR, Kris MG, Chan TA, DeAngelis LM, Omuro AM. PMID: 22089116.
      View in: PubMed   Mentions: 132     Fields:    Translation:Humans
    84. Neuroimaging: diagnosis and response assessment in glioblastoma. Cancer J. 2012 Jan-Feb; 18(1):26-31. Clarke JL, Chang SM. PMID: 22290254.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    85. Primary central nervous system lymphoma. Handb Clin Neurol. 2012; 105:517-27. Clarke JL, Deangelis LM. PMID: 22230516.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    86. Conditional probability of survival in patients with newly diagnosed glioblastoma. J Clin Oncol. 2011 Nov 01; 29(31):4175-80. Polley MY, Lamborn KR, Chang SM, Butowski N, Clarke JL, Prados M. PMID: 21969507; PMCID: PMC3208537.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    87. "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol. 2011 Dec; 13(12):1364-9. Grommes C, Oxnard GR, Kris MG, Miller VA, Pao W, Holodny AI, Clarke JL, Lassman AB. PMID: 21865399; PMCID: PMC3223088.
      View in: PubMed   Mentions: 159     Fields:    Translation:Humans
    88. Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? Neuro Oncol. 2011 Oct; 13(10):1118-24. Clarke JL, Ennis MM, Yung WK, Chang SM, Wen PY, Cloughesy TF, Deangelis LM, Robins HI, Lieberman FS, Fine HA, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Lamborn KR, Prados MD, North American Brain Tumor Consortium. PMID: 21813511; PMCID: PMC3177665.
      View in: PubMed   Mentions: 61     Fields:    Translation:Humans
    89. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol. 2010 Sep; 99(2):283-6. Clarke JL, Pao W, Wu N, Miller VA, Lassman AB. PMID: 20146086; PMCID: PMC3973736.
      View in: PubMed   Mentions: 108     Fields:    Translation:Humans
    90. Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide. Neuro Oncol. 2010 Mar; 12(3):274-82. Polley MY, Lamborn KR, Chang SM, Butowski N, Clarke JL, Prados M. PMID: 20167815; PMCID: PMC2940590.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCTClinical Trials
    91. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J Clin Oncol. 2009 Aug 10; 27(23):3861-7. Clarke JL, Iwamoto FM, Sul J, Panageas K, Lassman AB, DeAngelis LM, Hormigo A, Nolan CP, Gavrilovic I, Karimi S, Abrey LE. PMID: 19506159; PMCID: PMC2727290.
      View in: PubMed   Mentions: 74     Fields:    Translation:HumansCTClinical Trials
    92. Pseudoprogression and pseudoresponse: challenges in brain tumor imaging. Curr Neurol Neurosci Rep. 2009 May; 9(3):241-6. Clarke JL, Chang S. PMID: 19348713.
      View in: PubMed   Mentions: 81     Fields:    Translation:Humans
    93. External validation of the ICH score. Neurocrit Care. 2004; 1(1):53-60. Clarke JL, Johnston SC, Farrant M, Bernstein R, Tong D, Hemphill JC. PMID: 16174898.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    Jennifer's Networks
    Concepts (256)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (117)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-16-gff1bd585 on PROFILES-PWEB03.

    Copyright © The Regents of the University of California.